Literature DB >> 15334551

A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia.

Elena Belloni1, Maurizio Trubia, Marco Mancini, Valentina Derme, Mauro Nanni, Idoya Lahortiga, Roberta Riccioni, Stefano Confalonieri, Francesco Lo-Coco, Pier Paolo Di Fiore, Pier Giuseppe Pelicci.   

Abstract

A new complex rearrangement involving chromosome bands 5q13, 12p13, 22q11, and 3q12 was identified and characterized in a patient with acute myeloid leukemia. Fluorescence in situ hybridization showed the involvement of the ETV6 gene in 12p13. ETV6 primers were specifically designed for 3'- and 5'-RACE-PCR experiments, which led to the identification of the other two rearranged genes. The derivative chromosome 5 harbored a fusion of the ETV6 sequence with that of the LOC115548 gene. The two genes were placed in opposite orientation and did not encode a fusion protein. On the derivative chromosome 12, ETV6 was fused to the MN1 gene on chromosome 22. Also in this case, the insertion, within the MN1 sequence, of a portion of chromosome 3 prevented the formation of a fusion protein. Finally, the derivative chromosome 22 contained the 3' portions of both LOC115548 and MN1, and no fusion transcript with coding potential could be predicted. In conclusion, all chromosome breakpoints led to the truncation of the three involved genes in the absence of predicted fusion proteins. This study lends further support to the hypothesis that gene disruption resulting in either loss of function or haploinsufficiency may be relevant in acute myeloid leukemia pathogenesis. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334551     DOI: 10.1002/gcc.20081

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

2.  Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Authors:  Aurélie Bruno; Karim Labreche; Maïlys Daniau; Blandine Boisselier; Guillaume Gauchotte; Louis Royer-Perron; Amithys Rahimian; Frédéric Lemoine; Pierre de la Grange; Justine Guégan; Franck Bielle; Marc Polivka; Clovis Adam; David Meyronet; Dominique Figarella-Branger; Chiara Villa; Fabrice Chrétien; Sandrine Eimer; Frédéric Davi; Audrey Rousseau; Caroline Houillier; Carole Soussain; Karima Mokhtari; Khê Hoang-Xuan; Agusti Alentorn
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.

Authors:  Ines Martin-Padura; Paola Marighetti; Giuliana Gregato; Alice Agliano; Omar Malazzi; Patrizia Mancuso; Giancarlo Pruneri; Andrea Viale; Francesco Bertolini
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

4.  t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.

Authors:  Sarah B Mueller; Paola Dal Cin; Long P Le; Dora Dias-Santagata; Jochen K Lennerz; A John Iafrate; Hetal Desai Marble; Andrew M Brunner; Matthew J Weinstock; Marlise R Luskin; Daniel J De Angelo; Richard M Stone; Valentina Nardi
Journal:  Blood Adv       Date:  2022-01-08

5.  A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16).

Authors:  Abdulbasit Naiel; Michael Vetter; Olga Plekhanova; Elena Fleischman; Olga Sokova; Grigory Tsaur; Jochen Harbott; Sabrina Tosi
Journal:  Cancers (Basel)       Date:  2013-03-11       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.